---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-232722"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-05-20T20:36:22+00:00"
generated_at: "2026-05-20T20:38:08.140070+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M

## Summary
- Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
- Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.
- Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.
- Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.
- Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026.

## SEC filing metadata
- accession: 0001193125-26-232722
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-05-20T20:36:22+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/0001193125-26-232722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/d143790d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-232722
- JSON: https://secwatch.observer/filing/0001193125-26-232722.json
- Plain text: https://secwatch.observer/filing/0001193125-26-232722.txt

## Key facts
- Earnings Releases
  Jaguar Health, Inc. reported first quarter 2026 results: revenue $20,272, net income $(7,015), EPS $(13.60).
  - Period: first quarter 2026
  - Revenue: $20,272
  - Net income: $(7,015)
  - EPS: $(13.60)
  - Result: reported results
  source text: per share amounts) 2026 2025 $ change % change License and grant revenue, net $ 19,068 $ 43 19,025 44244 % Product revenue, net 1,204 2,171 (967 ) -45 % Total revenue, net $ 20,272 $ 2,214 18,058 816 % Income (loss) from operations $ 10,182 $ (9,421 ) 19,602 208 % Net loss attributable to common stockholders $ (7,015 ) $ (10,464 ) 3,449 33 % Net loss per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/0001193125-26-232722-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.